Endotronix’s Cordella System Cuts Heart Failure Hospitalizations by 49%, Study Shows

Endotronix's Cordella System Cuts Heart Failure Hospitalizations by 49%, Study Shows

by John Conrad| Oct 1, 2024| Member News

Endotronix, an Edwards Lifesciences company, has announced groundbreaking one-year clinical results for their Cordella Pulmonary Artery (PA) Sensor System, marking a significant advancement in heart failure management. The data, presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, reveals the system's potential to transform the care of heart failure patients.

The PROACTIVE-HF study, which involved 456 patients, demonstrated remarkable outcomes. Most notably, the study showed a 49% reduction in heart failure hospitalization and all-cause mortality rate. This substantial improvement in patient outcomes is complemented by significant enhancements in quality of life metrics. Patients experienced a 5% increase in the Kansas City Cardiomyopathy Questionnaire score, a 3% improvement in the 6-minute walk test, a 2% enhancement in New York Heart Association classification, and a 7% reduction in NT-proBNP levels, a key heart failure biomarker.

Dr. Liviu Klein, the national principal investigator of the PROACTIVE-HF trial, emphasized the consistency and compelling nature of the data. He noted that the trial results underscore the impact of comprehensive data, including seated PA pressure and vital signs, in improving outcomes and engaging patients in their care. This holistic approach to data collection and analysis appears to be a key factor in the system's success.

The Cordella solution offers a proactive, data-driven approach to heart failure management. At its core is the Cordella Sensor, an implantable device that directly measures pulmonary artery pressure. This capability allows for early detection of congestion and enables targeted therapy, potentially preventing hospitalizations and improving patient quality of life.

While these results are undoubtedly promising, it's important to note that forward-looking statements are subject to risks and uncertainties. Investors and patients alike should stay informed about ongoing developments and consult with healthcare professionals for personalized advice. The potential impact of the Cordella system on heart failure management is significant, but as with all medical advancements, careful consideration and ongoing research will be crucial.

For those interested in learning more about Endotronix and the Cordella system, detailed information is available at www.endotronix.com. As heart failure continues to be a major health concern worldwide, innovations like the Cordella system offer hope for improved patient outcomes and quality of life.

This article is based on a press release dated September 28, 2024, from Endotronix, an Edwards Lifesciences company.